Core Viewpoint - The approval of LBL-047 by the FDA marks a significant milestone for the company, indicating its potential as a first-in-class therapeutic option targeting both BDCA2 and TACI, which currently has no approved or clinical counterparts globally [1] Company Overview - The company,维立志博, has seen its stock price increase by approximately 3.45%, reaching 66 HKD, with a trading volume of 23.94 million HKD [1] - The company currently has 14 drug candidates, with 6 in clinical stages, including 1 core product and 3 major products [1] Product Details - LBL-047 is a bispecific fusion protein composed of a humanized anti-BDCA2 antibody and a modified TACI extracellular domain, showcasing its unique mechanism of action [1] - The core product, LBL-024, is a PD-L1 and 4-1BB bispecific antibody currently in the registration clinical stage, being evaluated for its efficacy against various cancers, including advanced lung neuroendocrine carcinoma and non-small cell lung cancer [1]
维立志博-B午后涨近4% 自研药物LBL-047取得美国FDA的新药临床试验批准